VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.85%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-6.22%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| 1 |
Brookfield Infrastructure
BIPC
|
$1.15M |
| 2 |
ECC
Eagle Point Credit Co
ECC
|
$1.05M |
| 3 |
OXLC
Oxford Lane Capital
OXLC
|
$1.03M |
| 4 |
ORAN
Orange
ORAN
|
$395K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
$391K |
Top Sells
| 1 |
Delek Logistics
DKL
|
$2.05M |
| 2 |
Western Midstream Partners
WES
|
$788K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
$657K |
| 5 |
Lamar Advertising Co
LAMR
|
$515K |
Sector Composition
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Vanda Pharmaceuticals
VNDA
$272M
| $529K | 0.28% |
54,777
+4,614
| +9% | +$44.6K |
|
127
Nuveen Credit Strategies Income Fund
JQC
$746M
| $528K | 0.28% |
89,308
-16,198
| -15% | -$95.8K |
|
128
Acadia Pharmaceuticals
ACAD
$4.26B
| $526K | 0.28% |
12,748
+1,074
| +9% | +$44.3K |
|
129
Sarepta Therapeutics
SRPT
$1.96B
| $517K | 0.27% |
3,679
+310
| +9% | +$43.6K |
|
|
GBT
130
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $514K | 0.27% |
9,328
+786
| +9% | +$43.3K |
|
131
Karyopharm Therapeutics
KPTI
$57.2M
| $511K | 0.27% |
2,333
+196
| +9% | +$42.9K |
|
132
United Therapeutics
UTHR
$18.1B
| $511K | 0.27% |
5,064
+427
| +9% | +$43.1K |
|
133
Ligand Pharmaceuticals
LGND
$3.25B
| $510K | 0.27% |
8,582
+722
| +9% | +$42.9K |
|
134
Gilead Sciences
GILD
$143B
| $505K | 0.26% |
7,992
+680
| +9% | +$43K |
|
|
CLVS
135
DELISTED
Clovis Oncology, Inc.
CLVS
| $504K | 0.26% |
86,459
+7,282
| +9% | +$42.4K |
|
|
RDUS
136
DELISTED
Radius Health, Inc.
RDUS
| $504K | 0.26% |
44,481
+3,747
| +9% | +$42.5K |
|
137
New Mountain Finance
NMFC
$1.13B
| $503K | 0.26% |
52,605
-25,147
| -32% | -$240K |
|
|
MRTX
138
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $501K | 0.26% |
3,020
-404
| -12% | -$67K |
|
139
Esperion Therapeutics
ESPR
$540M
| $500K | 0.26% |
13,442
+1,132
| +9% | +$42.1K |
|
140
Neurocrine Biosciences
NBIX
$14.3B
| $490K | 0.26% |
5,091
+284
| +6% | +$27.3K |
|
141
TG Therapeutics
TGTX
$5.11B
| $480K | 0.25% |
17,921
-2,461
| -12% | -$65.9K |
|
142
Hercules Capital
HTGC
$3.49B
| $475K | 0.25% |
41,042
-5,064
| -11% | -$58.6K |
|
143
Ionis Pharmaceuticals
IONS
$9.76B
| $475K | 0.25% |
10,013
+843
| +9% | +$40K |
|
144
Nektar Therapeutics
NKTR
$764M
| $473K | 0.25% |
1,902
+161
| +9% | +$40K |
|
145
RAPT Therapeutics
RAPT
$214M
| $461K | 0.24% |
1,790
-244
| -12% | -$62.8K |
|
|
BGX
146
Blackstone Long-Short Credit Income Fund
BGX
$160M
| $456K | 0.24% |
35,437
-13,691
| -28% | -$176K |
|
147
Denali Therapeutics
DNLI
$2.26B
| $447K | 0.23% |
12,464
-1,710
| -12% | -$61.3K |
|
|
MYOK
148
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $447K | 0.23% |
3,282
-439
| -12% | -$59.8K |
|
|
BGB
149
Blackstone Strategic Credit 2027 Term Fund
BGB
$560M
| $444K | 0.23% |
36,328
-14,092
| -28% | -$172K |
|
150
XBiotech
XBIT
$89M
| $442K | 0.23% |
23,176
-3,164
| -12% | -$60.3K |
|